The Therapeutic Modulation of Growth Hormone Release

  • J. A. H. Wass
  • R. J. M. Ross
Conference paper
Part of the Neuroendocrine Perspectives book series (NEUROENDOCRINE, volume 6)


Growth hormone is under the hypothalamic control of two different peptides: growth hormone-releasing hormone (GRF) and somatostatin. It is clear that of these two peptides, GRF is more important because pituitary stalk section results in growth hormone deficiency in man (1). Currently, we are in an exciting phase of our understanding of the neuroregulation of growth hormone. The structure of GRF was simultaneously discovered by Guillemin and Vale in 1982 (2,3). More is known about somatostatin because of its earlier discovery in 1973 (4).


Growth Hormone Growth Hormone Secretion Growth Hormone Response Growth Hormone Release Hypothalamic Extract 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Roth J, Glick SM, Yalow RS, Berson SA (1963) Hypoglycemia: a potent stimulus to secretion of growth hormone. Science 140: 987–988PubMedCrossRefGoogle Scholar
  2. 2.
    Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB (1982) Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 218: 585–587PubMedCrossRefGoogle Scholar
  3. 3.
    Rivier J, Speiss J, Thorner MO, Vale W (1982) Characterization of a growth hormone-releasing factor from a human pancreatic islet tumor. Nature 300: 1321–1328CrossRefGoogle Scholar
  4. 4.
    Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 178: 77–79CrossRefGoogle Scholar
  5. 5.
    Krieger DT, Glick S, Silverberg A, Krieger HP (1968) A comparative study of endocrine tests in hypothalamic disease. Circadian periodicity of plasma 11-OHCS levels, plasma 11-OHCS and growth hormone response to insulin hypoglycemia and metyrapone responsiveness. J Clin Endocrinol Metab 28: 1589–1598PubMedCrossRefGoogle Scholar
  6. 6.
    Abrams RL, Parker ML, Blanco S, Reichlin S, Daughaday WH (1966) Hypothalamic regulation of growth hormone secretion. Endocrinology 78: 605–613PubMedCrossRefGoogle Scholar
  7. 7.
    Frohman LA, Bernadis LL, Burek L, Maran JW, Dhariwal APS (1971) Hypothalamic control of growth hormone secretion in the rat. Program, 2nd International Symposium on Growth Hormone, Milan, 1971. Abstract 21: 12Google Scholar
  8. 8.
    Nemeroff CB, Konkol RJ, Bissette G, Youngblood W, Martin JB, Brazeau P, Rone MS, Prang A J, Breese GR, Kizer JS (1977) Analysis of the disruption in hypothalamic pituitary regulation in rats treated with monosodium-L-glutamate (MSG): evidence for involvement of the tubero-infundibular cholinergic and dopaminergic systems in neuroendocrine regulation. Endocrinology 101: 613–622PubMedCrossRefGoogle Scholar
  9. 9.
    Desy L, Pelletier G (1977) Immunohistochemical localization of somatostatin in the human hypothalamus. J Cell and Tissue Research 184: 491–497Google Scholar
  10. 10.
    Luedbeck D, Mueller D, Patino C (1976) Effects of stereotaxis in the human hypothalamus and limbic system on ACTH and GH secretion. Abstract 662 of the 5th International Congress of Endocrinology, Hamburg 1976Google Scholar
  11. 11.
    Frantz J, Haselbch CH, Libert O (1962) Studies of the effect of hypothalamic extracts on somatotrophic pituitary function. Acta Endocrinology 41: 336–350Google Scholar
  12. 12.
    Deuben RR, Meites J (1964) Stimulation of pituitary growth hormone by a hypothalamic extract in vivo Endocrinology 74: 408–414PubMedCrossRefGoogle Scholar
  13. 13.
    Schally AV, Arimura A, Wakabayashi I, Sawand S, Barret JF, Bowers CY, Redding TW, Mittler JG, Saito M (1970) Chemistry of hypothalmic growth hormone-releasing hormone (GRH). In: Meites J (Ed) Hypophysiotropic Hormones of the Hypothalamus: Assay and Chemistry. Baltimore: Williams and Wilkins: pp 208–222Google Scholar
  14. 14.
    Ling N, Esch F, Bolten P, Brazeau P, Wehrenberg WB, Guillemin R (1984) Isolation, primary structure, and synthesis of hyman hypothalamic somatocrinin: Growth hormone-releasing factor. Proc Natl Acad Sci USA 81: 4302–4306PubMedCrossRefGoogle Scholar
  15. 15.
    Thorner MO, Rivier J, Speiss J, Borges JLC, Vance ML, Bloom SR, Rogol AD, Cronin MJ, Daiser DL (1983) Human pancreatic growth hormone-releasing factor selectively stimulates growth hormone secretion in man. Lancet i: 24–28CrossRefGoogle Scholar
  16. 16.
    Grossman A, Savage MO, Wass JAH, Lytras N, Sueiras-Diaz J, Coy DH, Besser GM (1983) Growth hormone-releasing factor in growth hormone deficiency: the demonstration of a hypothalamic defect in growth hormone release. Lancet ii: 137–138CrossRefGoogle Scholar
  17. 17.
    Esch FS, Bohlen P, Ling NC, Brazeau PE, Wehrenberg WB, Guillemin R (1983) Primary structures of three human pancreas peptides with growth hormone-releasing activity. J Biol Chem 258: 1806–1812PubMedGoogle Scholar
  18. 18.
    Hammer RE, Brinster RL, Rosenfeld MG, Evans RM, Mayo KE (1985) Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth. Nature 315: 413–416PubMedCrossRefGoogle Scholar
  19. 19.
    Gelato MC, Pescovitz O, Cassorla F, Loriauz L, Merriam GR (1983) Effects of a growth hormone releasing factor in man. J Clin Endocrinol Metab 57: 674–676PubMedCrossRefGoogle Scholar
  20. 20.
    Rosenthal SM, Schriock EA, Kaplan SL, Guillemin R, Grumbach MM (1983) Synthetic human pancreas growth hormone-releasing factor (hpCRFl-44-NH2) stimulates growth hormone secretion in normal men. J Clin Endocrinol Metab 57: 677–679PubMedCrossRefGoogle Scholar
  21. 21.
    Sassolas G, Chatelain P, Cohen R, Boissel JP, Laporte S, Galleyrand J, Claustrat B, Elmcharfl A, Chayvialle JA, Cohen H, Ferry S, Underwood L (1984) Effects of human pancreatic tumor growth hormone-releasing hormone (hpGRHl-44-NH2) on immunoreactive and bioactive plasma growth hormone in normal young men. J Clin Endocrinol Metab 59: 705–709PubMedCrossRefGoogle Scholar
  22. 22.
    Grossman A, Savage MO, Lytras N, Coy DH, Rees LH, Besser GM (1984) Responses to analogues of growth hormone-releasing hormone in normal subject, and in growth-hormone deficient children and young adults. Clin Endocrinol 21: 321–330CrossRefGoogle Scholar
  23. 23.
    Losa M, Schopohl J, Muller OA, von Werder (1984) Stimulation of growth hormone secretion with human growth hormone releasing factor (GRF1–44, GRF1–40, GRF1–29) in normal subject. Klinische Wochen-shrift 62: 1140–1143CrossRefGoogle Scholar
  24. 24.
    Shibasaki T, Hotta M, Masuda A, Imaki T, Obara N, Demura H, Ling N, Shizume K (1985) Plasma GH responses to GHRH and insulin-induced hypoglycemia in man. J Clin Endocrin Metab 60: 1265–1267CrossRefGoogle Scholar
  25. 25.
    Ross RJM, Tsagarakis S, Grossman A, Preece MA, Rodda C, Davies PSW, Rees LH, Savage MO, Besser GM (1987) Treatment of growth hormone deficiency with growth hormone-releasing hormone. Lancet 1: 5–7PubMedCrossRefGoogle Scholar
  26. 26.
    Ross RJM, Tsagarakis S, Grossman A, Nhagafoonf L, Touzel RJ, Rees LH, Besser GM (1987) GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control; studies with pyridostigmine and GRF. Clin EndocrinolGoogle Scholar
  27. 27.
    Thorner MO, Rescheke J, Chitwood J, Rogol AD, Furlanetto R, Rivier J, Vale W, Blizzard RM (1985) Acceleration of growth in two children treated with human growth hormone releasing factor. N Engl J Med 312: 4–9PubMedCrossRefGoogle Scholar
  28. 28.
    Smith PJ, Brook CGD, Rivier J, Vale W, Thorner MO (1986) Nocturnal pulsatile growth hormone-releasing hormone treatment in growth hormone deficiency. Clin Endocrinol 25: 35–44CrossRefGoogle Scholar
  29. 29.
    Ross RJM, Tsagarakis S, Grossman A, Preece MA, Rodda C, Davies PSW, Rees LH, Savage MO, Besser GM (1987) Treatment of growth hormone deficiency with growth hormone-releasing hormone. Lancet 1: 5–7PubMedCrossRefGoogle Scholar
  30. 30.
    Ross RJM, Grossman A, Davies PSW, Savage MO, Besser GM (1987) Stilboestrol pretreatment of children with short stature does not effect the GH response to growth hormone-releasing hormone. Clin Endocrinol 27: 155–161CrossRefGoogle Scholar
  31. 31.
    Rochiccioli PE, Tauber M, Uboldi F, Coude F, Morre M (1986) Effect of overnight constant infusion of human growth hormone (GH)-releasing hormone-(l-44) on 24-hour GH secretion in children with partial GH deficiency. J Clin Endocrinol Metab 63: 1100–1105PubMedCrossRefGoogle Scholar
  32. 32.
    Krulich L, Dhariwal APS, McCann SM (1968) Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 6: 783–790CrossRefGoogle Scholar
  33. 33.
    Emson PC, Rossor M, Lee CM (1981) The regional distribution and chromatographic behavior of somatostatin in human brain. Neuroscience Let 22: 319–324CrossRefGoogle Scholar
  34. 34.
    Wass JAH (1982) Somatostatin and its physiology in man in health and disease. In: Besser GM and Martini L (Eds) Clinical Neuroendocrinology, Volume II. New York: Academic Press: pp 359–395Google Scholar
  35. 35.
    Hall R, Besser GM, Schally AV, Coy DH, Evered D, Goldie DJ, Dastin AJ, McNeilly AS, Mortimer CH, Turnbridge WHG (1973) Action of growth hormone release inhibitory hormone in healthy men and in acromegaly. Science 318: 518–584Google Scholar
  36. 36.
    Prange Hansen A A, Orskov H, Seyer-Hansen K, Lundbaek D (1973) Some actions of growth hormone release inhibiting factor. Br Med J iii: 523–524CrossRefGoogle Scholar
  37. 37.
    Mortimer CH, Carr D, Lind T, Mallinson CN, Schally AV, Turnbridge WMG, Yeomans L, Coy DH, Kastin A J, Besser GM, Hall R (1974) Effects of growth hormone release inhibiting hormone on circulating glucagon, insulin and growth hormone in normal, diabetic, acromegalic and hypopituitary patients. Lancet i: 697–701CrossRefGoogle Scholar
  38. 38.
    Besser GM, Mortimer CH, Carr D, Schally AV, Coy DH, Evered D, Kastin AJ, Turngridge WMG, Thorner MO, Hall R (1974) Growth hormone release inhibiting hormone in acromegaly. Brit Med J i: 352–355CrossRefGoogle Scholar
  39. 39.
    Bauer W, Briner U, Döpfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201–995: a very potent selective octapeptide analogue with prolonged action. Life Sci 31: 1133–1140CrossRefGoogle Scholar
  40. 40.
    Plewe G, Beyer J, Krause U, Neufeld M, Del Pozo E (1984 Long-acting and a selective suppression of growth hormone secretion by somatostatin analog SMS 201–995 in acromegaly. Lancet 2: 782–784PubMedCrossRefGoogle Scholar
  41. 41.
    Lamberts SWJ, Uitterlinden P, Verschoor L, Van Dongen KJ, Del Pozo E (1985) Long-term treatment of acromegaly with somatostatin analog SMS 201–995. N Engl J Med 313: 1576–1580PubMedCrossRefGoogle Scholar
  42. 42.
    Wass J AH, Lytras N, Besser GM (1986) Somatostatin octapeptide (SMS 201–005) in the medical treatment of acromegaly. Scand J Gastroenterol 21, Supplement 119: 136–140CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • J. A. H. Wass
    • 1
  • R. J. M. Ross
    • 1
  1. 1.Department of EndocrinologySt. Bartholomew’s HospitalLondonUK

Personalised recommendations